CD274 and non-small cell lung carcinoma: We previously reported that BMI independently predicted survival outcome, as patients with high BMI (BMI ≥21.4 kg/m2) demonstrated significantly better OS compared to those with low BMI (BMI <21.4 kg/m2) among patients with NSCLC expressing high PD-L1 who were administered first-line pembrolizumab monotherapy (46).